Cargando…
Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
The clinical success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles. It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent. Here we r...
Autores principales: | Apsel, Beth, Blair, Jimmy A., Gonzalez, Beatriz Z., Nazif, Tamim M., Feldman, Morri E., Aizenstein, Brian, Hoffman, Randy, Williams, Roger L., Shokat, Kevan M., Knight, Zachary A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880455/ https://www.ncbi.nlm.nih.gov/pubmed/18849971 http://dx.doi.org/10.1038/nchembio.117 |
Ejemplares similares
-
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009) -
Inhibitor Hijacking of Akt Activation
por: Okuzumi, Tatsuya, et al.
Publicado: (2009) -
Discovery of talmapimod analogues as polypharmacological anti-inflammatory agents
por: Liu, Wandong, et al.
Publicado: (2019) -
Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007) -
Evolution of kinase polypharmacology across HSP90 drug discovery
por: Antolin, Albert A., et al.
Publicado: (2021)